Concerning the pathological complete response (pCR) data, in the HR+ cohort, the authors observed a lower pCR in patients with HER2-low breast cancer compared to those with HER2-zero disease with no effect on long-term survival (Denkert et al., 2021). The gene discussed is ERBB2; the disease is breast cancer.